Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors?
The mechanisms by which increased urinary protein concentrations lead to nephrotoxic injury are certain to be multifactorial and involve complex interactions between numerous pathways of cellular damage mediated by both cellular and humoral pathways. These may include a major role for the podocyte in glomerular diseases leading to chronic renal failure, the loss of microvascular endothelium, the albumin-induced upregulation of renal cytokines and growth factors that promote tubulointerstitial injury by inflammation and fibrogenesis, and the role of complement-mediated tubulointerstitial injury due to proteinuria. This review will focus on the last mechanism, and emphasize recent studies implicating a primary role for activation of complement in proteinuric urine as the principal mediator of tubulointerstitial damage and progressive renal disease in various experimental animal models of nephrosis. It will be our contention that intraluminal activation of the terminal complement cascade leading to the formation of the C5b-9 membrane attack complex is the principal mediator of chronic progressive interstitial damage and progressive renal failure irrespective of the type of primary glomerular injury. This paradigm has important implications for the potential therapeutic role of complement inhibitors that are currently being developed.
Hsu
Stephen I-Hong
SI
Institute of Prevention and Research, National Kidney Foundation of Singapore. mdchsus@nus.edu.sg
Couser
William G
WG
D002908:Chronic Disease; D003167:Complement Activation / Q000187:drug effects* / Q000502:physiology; D003169:Complement Inactivator Proteins / Q000008:administration & dosage; D018450:Disease Progression; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D009395:Nephritis, Interstitial / Q000150:complications*; D011379:Prognosis; D011507:Proteinuria / Q000150:complications*; D018570:Risk Assessment; D012720:Severity of Illness Index
D003169:Complement Inactivator Proteins